SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS
Delisted
SYRS was delisted on the 19th of March, 2025.
70 hedge funds and large institutions have $291M invested in Syros Pharmaceuticals, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 31 increasing their positions, 14 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
70
Holders Change
+8
Holders Change %
+12.9%
% of All Funds
1.38%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
17
Increased
31
Reduced
14
Closed
9
Calls
$956K
Puts
–
Net Calls
+$956K
Net Calls Change
-$592K
Top Buyers
1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$8.59M |
2 |
![]()
JPMorgan Chase & Co
New York
|
+$3.63M |
3 |
Millennium Management
New York
|
+$3.5M |
4 |
SCM
Sio Capital Management
New York
|
+$3.1M |
5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$2.36M |
Top Sellers
1 |
RG
Redmile Group
San Francisco,
California
|
-$25.4M |
2 |
6CM
683 Capital Management
New York
|
-$4.46M |
3 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$3.74M |
4 |
BBA
Baker Bros. Advisors
New York
|
-$1.97M |
5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$1.75M |